The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has BioLife Solutions (BLFS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BioLife Solutions is one of 756 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BLFS is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BLFS's full-year earnings has moved 650% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, BLFS has returned 178.33% so far this year. Meanwhile, the Medical sector has returned an average of 11.06% on a year-to-date basis. This means that BioLife Solutions is outperforming the sector as a whole this year.
Looking more specifically, BLFS belongs to the Medical - Products industry, which includes 69 individual stocks and currently sits at #178 in the Zacks Industry Rank. On average, stocks in this group have gained 21.38% this year, meaning that BLFS is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BLFS as it attempts to continue its solid performance.